KA-2886-LD38 / KYinno, Escugen Biotechnology - LARVOL DELTA

KA-2886-LD38: a bispecific antibody-drug conjugate (ADC) targeting both EGFR and MET, incorporating a novel linker-payload that inhibits DNA topoisomerase I (AACR 2025) - "Compared to the benchmark ADC AZD9592, KA-2886-LD38 exhibits a similar internalization rate when binding to tumor cells but demonstrates significantly stronger cytotoxicity and bystander killing activity across different tumor cell lines in vitro...Moreover, KA-2886-LD38, when combined with osimertinib, also demonstrated a combination inhibitory effect on H1975 tumor growth. KA-2886-LD38 is well-tolerated at doses up to 30 mg/kg in EGFR and MET humanized genetically modified mice, and toxicity studies in monkeys are ongoing. These results suggest that KA-2886-LD38 has remarkable potential in the landscape of anti-EGFR/cMet therapies."

Breast Cancer • Colorectal Cancer • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • EGFR • TOP1